title: Emerging antivirals for the treatment of hepatitis B.
abstract: Chronic infection with hepatitis B virus (HBV) constitutes a major global public health threat, causing substantial disease burdens such as liver cirrhosis and hepatocellular carcinoma, thus representing high unmet medical needs. Currently available therapies are safe, well tolerated, and highly effective in decreasing viremia and improving measured clinical outcomes with low rates of antiviral resistance. However, long-term management remains a clinical challenge, mainly due to the slow kinetics of HBV surface antigen clearance. In this article, we review emerging antivirals directed at novel targets derived from mechanisms of viral cellular entry, viral replication, viral assembly, and the host immune response, leading to preclinical and clinical trials for possible future therapeutic intervention. The recent therapeutic advances in the development of all categories of HBV inhibitors may pave the way for regimens of finite duration that result in long-lasting control of chronic hepatitis B infection.
authors: Xue-Yan Wang, Hong-Song Chen, Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
authors: Xue-Yan
authors: XY
authors: Wang
authors: Xue-Yan Wang, Hong-Song Chen, Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
authors: Hong-Song
authors: HS
authors: Chen
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000472:pathogenicity; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Antiviral; Hepatitis B; Non-nucleoside antivirals; Nucleoside analogue; Nucleotide analogue